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translating the approach of the Global Burden of Disease studies from a societal to an individual level:
Instead of calculating ”years lived with disability”, we suggest estimating ”time lost due to an attack”.
METHODS Time lost due to an attack is calculated by multiplying the duration and the degree of
impaired functioning during an attack. RESULTS Time lost due to an attack, different from other
outcome measures, does not just focus on the short-term analgesic effects of treatments, but rather
on the improvement of all migraine symptoms and restoration of functioning, also considering therapy-
related impairment. Importantly, time lost due to an attack measures the entire time patients are not
functioning normally, from onset to complete resolution. CONCLUSIONS Time lost due to an attack
represents a new paradigm to assess migraine burden in single patients for a patient-centered evaluation
of both acute and prophylactic treatments.
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Abstract 
Objective We propose a new outcome measure to assess the efficacy of 
migraine treatments translating the approach of the Global Burden of Disease 
studies from a societal to an individual level, as instead of calculating “Years 
lived with Disability”, we suggest estimating “Time Lost due to an Attack” (TLA).  
Methods TLA is calculated by multiplying the duration and the degree of 
impaired functioning during an attack.  
Results. TLA, different from other outcome measures, does not just focus on 
the short-term analgesic effects of treatments, but rather on the improvement of 
all migraine symptoms and restoration of functioning, also considering therapy-
related impairment. Importantly, TLA measures the entire time patients are not 
functioning normally, from onset to complete resolution.  
Conclusions. TLA represents a new paradigm to assess migraine burden in 
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Introduction 
Since the triptan era, changes in pain intensity were assessed to provide 
evidence of acute efficacy of novel treatments. Generally, the proportion of 
patients with a reduction from moderate or severe to “no or only mild pain” or 
“no pain at all” at 2 hours post-dose was the preferred primary outcome 
measure in clinical trials.[1, 2] More recently, the Food and Drug Administration 
has added “resolution of the most bothersome associated feature at 2 hours 
post-dose” as co-primary endpoint, acknowledging that migraine attacks are 
more than just painful episodes.[1, 3] 
It is important to realize that, in clinical trials, patients are required to treat 
migraine attacks only when the headache has reached moderate or severe 
intensity.[2, 4, 5] Although somewhat artificial and arbitrary, there are a number 
of methodological advantages of this strategy. When the headache reaches a 
moderate or severe intensity, there usually are other associated features as 
well,[6] ensuring that migraine attacks are being treated – not featureless and 
usually milder tension-type headaches. This should minimize the placebo 
response and increase the validity of the results. Moreover, it also simplifies and 
standardizes the assessment procedure, as measurements are always made 
from a similar baseline pain intensity rather than from different levels. After all, 
improvement from severe to moderate pain is not the same as improvement 
from mild to no pain. 
However, the recommended endpoint also has important disadvantages, 
preventing straightforward extrapolation of the results to clinical practice, where 
patients usually prefer treating attacks as soon as possible to limit the ictal 
burden.[4, 7, 8] Moreover, when treating early, prior to development of central 
sensitization, efficacy might also be higher.[4, 5, 9, 10] In addition, measuring 
efficacy until 2 hours post-dose only, does not take into account that 
approximately one third of patients get a relapse within 24 hours after initial 
improvement.[1] Sustained pain freedom (i.e. pain-free by 2 hours post dose 
and for the subsequent 22 hours, without recurrence of the headache) would be 
a clinically more relevant endpoint.[4, 5, 11] 
Migraine attacks are more than just pain. The headache phase is typically 
preceded, accompanied, and/or followed by other – often also highly disabling – 
features; examples are photophobia, phonophobia, nausea, vomiting, fatigue, 
and mood and cognitive changes.[6, 12, 13] These non-pain symptoms also 
contribute to the overall burden of migraine attacks and may incapacitate 
patients for longer periods than just the headache phase.[6, 12, 14] Recent 
studies have tested these symptoms as secondary endpoints, but have not yet 
used a standardized approach.[15] Finally, pain endpoints do not take into 
account possible treatment-related adverse events. 
While sensitive and specific in assessing efficacy of putative new acute 
migraine treatments versus placebo,[16-20] the recommended endpoint[1] has 
been much less useful in differentiating the effectiveness of active acute 
treatments. For instance, direct comparator trials using the recommended 
outcome measure have nearly all have failed in detecting significant 
antimigraine differences between triptans and simple analgesics[21] – yet, many 
experts and patients would agree that triptans are clinically more effective. 
In brief, the strategy to assess antimigraine efficacy by focusing on short-term 
analgesic effects in patients instructed to wait until the pain is moderate or 
severe does not seem to reflect good clinical practice. Potentially relevant effect 
differences between two active treatments may easily be missed. The resolution 
of pain from a moderate or severe intensity has proven a good primary endpoint 
to provide evidence of acute efficacy of a new agent against placebo; to 
compare agents with already proven efficacy, we propose to estimate the “time 
lost due to an attack”. This novel patient-reported outcome measure takes the 
aforementioned considerations into account and is likely to be more sensitive in 
detecting clinically relevant differences between different treatment approaches. 
Time lost due to an attack 
Experiencing a severe migraine attack is highly disabling.[14, 22, 23] During 
attacks, patients cannot function normally and lose time that they would rather 
have spent differently. We propose translating the approach chosen in the 
Global Burden of Disease studies[14] from a societal to an individual level. 
Instead of calculating “Years lived with Disability”, we suggest estimating “Time 
Lost due to an Attack” (TLA), using the following formula: 
𝑡𝑡 = 𝑑𝑑 ∗ (1 − 𝑓𝑓
100
) 
Here, 𝑡𝑡 denotes the time lost due to an attack. In addition, 𝑑𝑑 represents the 
attack duration (in hours) and f the level of functioning. The duration of the 
attack is defined as the total duration of impaired function since the onset of 
pain– not just the duration of pain. 
Subtracting 
𝑓𝑓100 from 1 converts the level of functioning into the level of 
impairment on a scale from 0 to 1. Multiplying the level of impairment with the 
duration of the attack results in TLA. 
We believe that it is easier for patients to rate functioning (a positive concept) 
than disability (a negative concept).  
We suppose that most people are intuitively able to estimate their level of 
functioning. A more precise definition could be the following: the level of 
functioning is measured on a scale from 0 to 100 and corresponds to the 
proportion of planned activities actually executed. Zero implies that one has 
been unable to do anything because of pain or associated features; 100 implies 
that everything has been done as planned. 
This approach only leads to a rough estimate as a constant level of impairment 
is assumed for the whole attack. Precision increases if patients assess their 
functioning at multiple time points, which – for practical reasons – should be 
assessed using digital diaries. 
Although single records are possible, they might not reflect the variability of 
functioning during an attack. Ideally, the number of assessments with TLA for 
each attack ranges from an essential minimum of 4 (baseline, time of acute 
drug administration, 2 hours post-dose, 48 hours post-dose) to a higher number 
of them, which may be signal-driven (e.g. onset of a relapse) or pre-planned 
(e.g. every 2 hours for 48 hours). 
According to current international consensus, “disability lies on a continuum 
from no disability (full functioning) to complete disability” and fluctuates during a 
person’s life in different domains and to varying degrees.[24] This issue is even 
more important in migraine attacks, during which the level of disability is likely to 
vary considerably, because of both the disease and its treatment. Hence, we 
are aiming to measure an intrinsically variable phenomenon (i.e. disability) in 
patients affected by a disease that intrinsically induces sudden and relevant 
variations of functioning (i.e. migraine). 
In that case, we assume that impairment 𝑚𝑚 (defined as 1 − 𝑓𝑓100) increases or 
decreases linearly between two measurements. So, changes are described by 
the following linear equation: 
𝑦𝑦 = (𝑚𝑚2 −𝑚𝑚1)
(𝑡𝑡2 − 𝑡𝑡1) 𝑥𝑥 + 𝑚𝑚1 
Here, 𝑡𝑡1 denotes the time of first record of functioning, and 𝑡𝑡2 the second. In 
addition, 𝑚𝑚1 is the level of impairment at 𝑡𝑡1; 𝑚𝑚2 is the level of impairment at 𝑡𝑡2. 
We will assume that 𝑡𝑡1 ≠ 𝑡𝑡2 and that 𝑡𝑡1 = 0 (hence, 𝑡𝑡2 equals the time span 𝑑𝑑 
between two measurements). Thus, TLA between 𝑡𝑡1 and 𝑡𝑡2 is: 




∗ (𝑚𝑚2 −𝑚𝑚1)𝑑𝑑 ∗ 𝑑𝑑2 + 𝑚𝑚1 ∗ 𝑑𝑑 = �12𝑚𝑚2 − 12𝑚𝑚1 + 12𝑚𝑚1� ∗ 𝑑𝑑 = (𝑚𝑚1 + 𝑚𝑚2)2 ∗ 𝑑𝑑 
TLA can then be calculated using the following formula. 
𝑇𝑇𝑇𝑇𝑇𝑇 = �𝑑𝑑𝑖𝑖 ∗ 𝑚𝑚𝑖𝑖−1 + 𝑚𝑚𝑖𝑖
2
𝑛𝑛
𝑖𝑖=1 = �𝑑𝑑𝑖𝑖 ∗ �1 − 12 ∗ 𝑓𝑓𝑖𝑖−1 + 𝑓𝑓𝑖𝑖100 �𝑛𝑛𝑖𝑖=1  
𝑛𝑛 denotes the number of times the patient assessed his level of functioning 
during the attack; 𝑓𝑓𝑖𝑖 indicates the level of functioning and 𝑑𝑑𝑖𝑖 the time passed 
since the last assessment. The recording of the level of functioning is started at 
the onset of an attack, which we define as the onset of pain. The level of 
functioning before the onset of the attack (status quo ante, SQA) needs to be 
recorded retrospectively and is referred to as 𝑓𝑓0.  
Changes of the level of functioning are recorded until the end of the attack, 
which we define as the return of the level of functioning to the baseline value 
(SQA). 
We propose assessing functioning at fixed time-points; nonetheless, 
measurements may also be adapted to specific needs. For example, for 
research purposes, the investigators may set specific time-points for the 
recording of functioning according to the specific aims of the study. 
Alternatively, in clinical practice, physicians may fix individual time-points for 
each patient, taking into consideration their attack profile. 
Sleep  
During sleep, again, we assume a linear increase or decrease of the level of 
functioning. Consequently, patients are required to record their level of 
functioning before dozing off and after waking.  
For example, if a patient suffering a migraine attack slept for eight hours and 
recorded a level of functioning of 50 just before going to sleep and 80 shortly 
after waking up, during that period, 2.8 hours were lost due to the attack. 
Should a patient notice a new-onset headache-related decreased functioning on 
waking up (i.e. an attack that has not been present before going to bed), we 
advise recording the level of functioning for the evening before retrospectively. 
Again, we assume a linear decrease of the level of functioning and recommend 
using the above-mentioned formula. 
Impact of premonitory symptoms 
If researchers are also interested in impairment caused by premonitory 
symptoms, which may occur up to 48 hours before the attack,[13] only minor 
adaptations are needed. In this case, patients are asked to record impairment 
retrospectively as soon as they have realized that they have a migraine attack. 
Alternatively, patients may be asked to register their level of functioning at 
specific times throughout the study period, irrespective of presence of pain. This 
would certainly prevent recall bias, but would increase the effort on part of the 
participants. 
A possible concern may emerge regarding the retrospective assessment of pre-
attack functioning. However, we suspect that the time lag from the onset of an 
attack to the beginning of the recording of functioning will be, in most cases, 
quite short. In addition, in research settings, periodic recordings of functioning 
could be planned to prevent any recall bias almost completely. 
Relapse 
Studies assessing pain as primary endpoint revealed that pain might return 
within 46 to 70 hours after initial complete resolution two hours post-dose 
(“relapse”, previously termed “recurrence”).[1] In this case, the attack cannot be 
considered as having ceased at two hours. Conceptually, “relapse” implies that 
drugs may suppress symptoms of a migraine attack, while the underlying 
processes continue; symptoms reappear as soon as the effect of the medication 
fades. 
When using TLA as endpoint, a transient return to the SQA would suggest the 
end of an attack although more time was to be lost due to the attack. Therefore, 
we recommend assuming a relapse, if the level of functioning drops within 48 
hours after it had reached the baseline value (SQA) at two hours post-dose. 
When impairment reaches the baseline value and does not rise anymore for the 
remainder of the 48-hours period, the attack has ended. Consequently, in order 
to detect a possible relapse, patients who reached SQA at two hours post-dose 
should be encouraged to continue recording for a further 46 hours. 
While in the past studies using “pain at two hours” as primary endpoint often 
monitored for recurrence during 22 hours,[25] we felt that this period is too short 
for the endpoint proposed in this article. Impairment during a migraine attack is 
not solely due to pain; functional impairment may occur during postdromes as 
well as because of side effects of the treatment.[12, 26] In accordance with 
guidelines published by the International Headache Society,[1] we propose 
monitoring for relapses for 48 hours post-dose. 
Other measurements 
We recommend including relapses of pain as secondary endpoint. Furthermore, 
additional information (pain localization, character, and intensity as well as 
associated features) may be recorded to validate the diagnosis of a migraine 
attack. 
Finally, we would like to stress the relevance of the TLA for special populations 
(i.e. patients with chronic headache, medication overuse headache, or 
psychiatric comorbidities such as anxiety or depression), in which the outcome 
marker may be a better real-world measure of the improvement with acute 
medications. For example, in patients with medication overuse headache, drug 
consumption may decrease when it becomes apparent that acute treatment 
reduces pain but does not improve functioning. 
We believe that assessing the TLA is likely more sensitive and more intuitive to 
use than the verbal numerical scale (0 = no disability; 1 = mild disability; 
2 = moderate disability; 3 = severe disability), the 24-hour MSQoL or the Minor 
Symptoms Evaluation Profile recommended by IHS Guidelines.[1] These 
advantages may help to delineate a more realistic profile of the evolution of a 
migraine attack, identify small changes, which are particularly relevant when 
symptoms are mild, and detect fading drug effects or relapses. In addition, the 
IHS-recommended Global Impact measurement of functioning requires patients 
to transform the level of functioning into the level of disability and refers to a 
general concept of normal daily living. By contrast, we suggest considering 
planned activities that the patient has been unable to do because of the 
migraine attack as reference to rate the functioning. 
To compare the relative value of different approaches, it would be useful to 
compare them in properly designed trials evaluating advantages and 
disadvantages of each available measure. In addition, the 24-hour MSQoL and 
the Minor Symptoms Evaluation Profile comprise more questions and 
undoubtedly require a more time and thought. It is likely that even repeated 
assessments of the level of functioning are less burdensome to patients than 
answering many different questions. From this point of view, TLA has potential 
strengths. 
Conclusions 
Migraine attacks result in reduced fitness for personal, professional, and social 
activities by limiting the ability to function normally. Often these constraints are 
not only due to pain, but also to other features of migraine attacks such as 
fatigue. Therefore, acute migraine outcome measures should not just focus on 
the short-term analgesic effects of a treatment, but rather on improvement of all 
migraine symptoms and restoration of normal functioning, in addition to possible 
impairment caused by the therapy. 
We propose TLA, calculated by multiplying the duration and the degree of 
impaired functioning as primary endpoint for future studies assessing the 
efficacy of acute migraine treatments. Of course, this approach is not limited to 
the evaluation of an acute treatment. If TLA is measured for every attack over 
the course of several weeks or months, changes in the total amount of lost time 
after the initiation of a preventive treatment correlate with its efficacy and 
tolerability. 
An additional advantage of TLA as a clinical trial endpoint is that, like in clinical 
practice, patients may treat attacks as soon as possible and are not required to 
wait until the headache has worsened to moderate or severe intensity. Finally, 
while the current 2-hour endpoint does not account for relapse, TLA will 
measure the entire time patients are not functioning normally, from onset to 
complete resolution. 
Although TLA has several strengths, validation is necessary before promoting 
its use for research purposes and in clinical practice. Accordingly, we have 
planned a validation study and the development of an open-access web-app 
automatically calculating TLA. 
Bullet points 
− Current endpoints for acute treatments focus on short-term analgesic effects, 
not assessing the entire treatment impact. 
− TLA summarizes, from attack onset to complete resolution, the status of all 
migraine symptoms and functioning, including therapy-related impairment.  
− TLA is a new patient-centered paradigm to assess migraine burden and 
evaluate acute and prophylactic treatments. 
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